文献速递中枢神经肿瘤放疗姑息放疗与转移瘤放疗物理与技术

15个及以上脑转移瘤患者立体定向放射外科治疗的安全性与可行性

Safety and Feasibility of Stereotactic Radiosurgery for Patients with 15 or more Brain Metastases.
PubMed 文献 · Adv Radiat Oncol · 2024-04-16

该研究纳入2014至2022年接受1至5次立体定向放射外科(SRS)治疗≥15个脑转移瘤的118例患者(共124疗程),评估安全性、认知结局与生存。任何级别放射性坏死发生率为15.3%,≥3级为3.2%;31例可评估患者中25例PROMIS评分稳定或改善。未接受过脑放疗者中位生存7.4个月,接受过者为4.6个月(P=0.034)。

要点

  • ≥15个脑转移瘤接受SRS,任何级别放射性坏死15.3%,≥3级3.2%。
  • 31例纵向评估中25例PROMIS评分稳定或改善。
  • 未接受过脑放疗者中位生存7.4个月,优于接受过者的4.6个月。

核心结论

  • SRS用于≥15个脑转移瘤患者是安全的,认知结局良好,生存与当代WBRT研究可比。
  • 初治患者中位生存超过6个月,足以从SRS的认知保护中获益。
  • 作者认为本研究支持开展比较SRS与海马保护WBRT的随机研究。

研究设计与样本

  • 回顾性分析本机构2014至2022年接受1至5次LINAC基础SRS治疗≥15个脑转移瘤的患者,共118例、124疗程。
  • 认知结局采用系列患者报告结局测量信息系统(PROMIS)评分客观评估。
  • 生存分析采用Kaplan-Meier法,组间比较采用log-rank检验。

主要发现

  • 每疗程治疗病灶中位数为20个(范围15-94个),81.5%患者接受24 Gy分3次的分次SRS。
  • SRS时19.4%患者曾接受WBRT,24.2%曾接受SRS。
  • 任何级别放射性坏死发生率为15.3%,≥3级放射性坏死为3.2%。
  • 31例纵向评估PROMIS评分者中25例评分稳定或改善。
  • 未接受过脑放疗者中位生存7.4个月 vs 接受过者4.6个月(P=0.034)。

临床怎么用

  • 作者认为SRS用于≥15个脑转移瘤患者安全且认知结局良好。
  • 作者认为初治患者中位生存超过6个月,足以从SRS的认知保护中获益。
  • 作者认为本研究支持开展比较SRS与海马保护WBRT的随机研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current standard of care treatment for patients with ≥15 brain metastases (BM) is whole brain radiation therapy (WBRT), despite poor neurocognitive outcomes. We analyzed our institutional experience of treating these patients with stereotactic radiosurgery (SRS), with the aim of evaluating safety, cognitive outcomes, and survival metrics. METHODS: Patients who received SRS for ≥15 BMs in 1 to 5 fractions from 2014 to 2022 were included. Cognitive outcomes were objectively evaluated using serial Patient-Reported Outcome Measurement Information System (PROMIS) scores. The Kaplan-Meier method was used for survival analysis and log-rank test for intergroup comparisons. RESULTS: Overall, 118 patients underwent 124 courses of LINAC-based SRS. The median number of lesions treated per course was 20 (range, 15-94). Most patients received fractionated SRS to a dose of 24 Gy in 3 fractions (81.5%). At the time of SRS, 19.4% patients had received prior WBRT, and 24.2% had received prior SRS. The rate of any grade radiation necrosis (RN) and grade ≥3 RN were 15.3% and 3.2%, respectively. When evaluating longitudinal PROMIS score trends, 25 of 31 patients had a stable/improved PROMIS score. Patients who did not receive prior brain RT had a longer median survival (7.4 months vs 4.6 months, P = .034). The 12m local control was 97.6%, and the cumulative incidence of distant intracranial failure, with death as a competing event, was 46% (95% CI, 36%, 55%). One year freedom from neurologic death, leptomeningeal disease, and salvage WBRT were 89%, 94.6%, and 84%, respectively. CONCLUSION: We present here one of the largest studies evaluating SRS for patients with ≥15 BMs. SRS was safe, had favorable cognitive outcomes, and had comparable survival outcomes to contemporary studies evaluating WBRT in this population. Treatment-naïve patients had a median survival of >6 months, long enough to benefit from cognitive sparing with SRS. Our study supports randomized studies comparing SRS and hippocampal avoidance WBRT approaches for these patients.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Upadhyay R, Palmer JD, Klamer BG, et al. Safety and Feasibility of Stereotactic Radiosurgery for Patients with 15 or more Brain Metastases. Adv Radiat Oncol. 2024. PMID: 38799108. doi:10.1016/j.adro.2024.101509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。